Journal
ADVANCED HEALTHCARE MATERIALS
Volume 8, Issue 18, Pages -Publisher
WILEY
DOI: 10.1002/adhm.201900720
Keywords
cascade-amplifying synergistic effects; on-demand drug release; ROS-responsive nanoparticles; sonochemotherapy
Funding
- National Natural Science Foundation of China [31771075, 81827801, 31470909]
- Fundamental Research Funds for the Central Universities [xzy022019055]
Ask authors/readers for more resources
Sonodynamic therapy (SDT) not only has greater tissue-penetrating depth compared to photo-stimulated therapies, but also can also trigger rapid drug release to achieve synergistic sonochemotherapy. Here, reactive oxygen species (ROS)-responsive IR780/PTL- nanoparticles (NPs) are designed by self-assembly, which contain ROS-cleavable thioketal linkers (TL) to promote paclitaxel (PTX) release during SDT. Under ultrasound (US) stimulation, IR780/PTL-NPs produce high amounts of ROS, which not only induces apoptosis in human glioma (U87) cells but also boosts PTX released by decomposing the ROS-sensitive TL. In the U87 tumor-bearing mouse model, the IR780/PTL-NPs releases the drug at the target sites in a controlled manner upon US irradiation, which significantly inhibits tumor growth and induces apoptosis in the tumor tissues with no obvious toxicity. Taken together, the IR780/PTL-NPs are a novel platform for sonochemotherapy, and can control the spatio-temporal release of chemotherapeutic drugs during SDT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available